Kaya, HakkiZorlu, AliYucel, HasanDogan, Omer TamerSarikaya, SavasAydin, GulayKivrak, TarikYilmaz, Mehmet Birhan2019-07-272019-07-282019-07-272019-07-2820151354-750X1366-5804https://dx.doi.org/10.3109/1354750X.2015.1045033https://hdl.handle.net/20.500.12418/7927Background: Cancer antigen-125 (CA-125) might be a useful biomarker to predict long-term mortality in patients with recent exacerbation of chronic obstructive pulmonary disease (COPD). Methods: A total of 87 consecutive patients with COPD were evaluated prospectively. Mean age of patients was 68 +/- 10 years (55% males, 45% females) with a median follow-up period of 49 months. Optimal cut-off value of CA-125 to predict mortality was found as >93.34 U/ml, with 91% specificity and 40% sensitivity. Results: After follow-up, 20 out of 87 (23%) experienced cardiovascular death. CA-125 levels were higher among those who died compared to those who survived [55 (12-264) versus 28 (5-245) U/ml, p = 0.013]. In multivariate Cox proportional-hazards model with forward stepwise method, only CA-125 > 93.34 U/ml on admission (HR 3.713, 95% Cl: 1.035-13.323, p = 0.044) remained associated with an increased risk of death. Conclusions: For the first time, we demonstrated that CA-125 helps the risk stratification of patients with COPD.en10.3109/1354750X.2015.1045033info:eu-repo/semantics/closedAccessCA-125cancer antigen-125chronic obstructive pulmonary diseaselong-term mortalityrisk stratificationArticle202167162259860742-s2.0-84934280863Q2WOS:000358062100010Q3